Login Streaming News Register
Menu
Special Research Report
HOW TO USE DISCUSSION BOARDS
Office Hours: 9:00 AM - 4:00 PM (EST) Monday - Thursday Call: 602-821-1102

Featured News ENZC

Enzolytics Announces the Signing of the Business Combination Agreement with Sagaliam Acquisition Corp (SAGA)
Biogenysis, Inc. Announces Partnering with Khalpey AI Lab and Contenta, Ltd. to Incorporate AI in Microbiome Analysis to Identify Biomarkers for Use in Accurately Predicting Alzheimer’s Disease Onset and Prevention.
Biogenysis’ International Patent Application, Covering Its Anti-SARS-CoV-2 Monoclonal Antibodies, Advances to Prosecution in Europe and as a U.S. National Stage Application.
Virogentics, Inc. Provides Update on African Project, European Medicine Agency Application and Clinical Trials for Application for Type 2 Diabetes
Virogentics, Inc to Introduce a Dietary Supplement Offers Additional Information on ITV-1 and Diabetic Clinical Trials
Biogenysis Inc. Announces a Collaboration with Khalpey AI Lab in using Artificial Intelligence (AI) for Unveiling Potential Biomarkers and Predicting the Onset or Prevention of Alzheimer’s Disease.
Enzolytics Inc. Files Supplemental Information Report on the Sale of Biogenysis, Inc. and Virogentics, Inc to Sagaliam Acquisition Corp.
Virogentics, Inc to Introduce a Dietary Supplement Offers Additional Information on ITV-1 And Diabetic Clinical Trials
Enzolytics, Inc. Reports Amendment to Non-Binding Term Sheet with the Special Purpose Acquisition Company Sagaliam Acquisition Corp.
Enzolytics Offers Update on Virogentics, Inc ITV-1 African Project
ENZC Quote | News | Filings | Discuss 0

Discussion ENZC

Login -or- Register to join the discussion.
NEWSLETTER
© 2023 Stock Day Media
Financial Market Data copyright © 2023 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Analyst Ratings by Zacks. Terms of Use.
Stock Day Media may receive direct compensation of $500 to $10,000 for content and or advertisements, that may be subject to disclaimer pursuant to Section 17(b) of the Securities Act of 1933. For those instances where it contains company or stock-specific mention, we provide the following list of compensation received in order to ensure full disclosure and transparency.
X
Search
Generic filters